Constitutive activation of SYK by gene fusion or overexpression has been implicated in hematopoietic malignancies, and SYK inhibitors have shown promise in clinical trials for lymphoma and leukemia (Friedberg et al, 2010). This evidence concerns the gene SYK and lymphoma.